The Neglected Transition
Menopause is a universal experience for women who live long enough to reach it. Its symptoms — vasomotor changes, sleep disruption, cognitive effects, musculoskeletal pain, mood changes, and genitourinary symptoms — can be severe and prolonged. And yet menopause care in the United States is fragmented, inconsistently covered, and often inaccessible.
Most primary care providers lack formal training in menopause management. Hormone therapy — the most evidence-based treatment for vasomotor symptoms — has been underutilized for two decades following a misinterpretation of the Women’s Health Initiative findings. The science has moved significantly; prescribing practice has not caught up.
The Workplace Dimension
The majority of women experiencing menopause are employed. More than half report that symptoms affect their work performance. A significant proportion have considered reducing hours or leaving jobs because of inadequately managed symptoms.
The economic cost of that lost productivity is substantial and almost entirely unmeasured. The talent attrition — skilled, experienced women leaving the workforce in midlife because the health system has failed them — is a systemic failure, not a personal one.
The Research Gap
Menopause research has been disproportionately conducted in white women. The timing, severity, and clinical management of menopause varies significantly across racial and ethnic groups. Clinical guidelines need to reflect this diversity, and future research investment must prioritize the populations currently underserved.
What We Track
We follow updates to hormone therapy clinical guidance, menopause care coverage decisions, workplace accommodation policy at federal and state levels, and NIH investment in midlife women’s health research.
